Companies › Cumberland Pharmaceuticals
1 active drug program in 2 registered trials: 2 Phase 2; Immunology, Respiratory; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ifetroban Sodium Thromboxane A2 receptor (TP receptor) antagonist | TBXA2R | Phase 2 | Scleroderma, Diffuse; Idiopathic Pulmonary Fibrosis | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02682511 | Ifetroban Sodium | Phase 2 | Scleroderma, Diffuse | Immunology | Mar 2026 |
| NCT05571059 | Ifetroban Sodium | Phase 2 | Idiopathic Pulmonary Fibrosis | Respiratory | Jan 2028 |
Cash of $4m on 2026-06-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Prana Therapies Enveda Therapeutics Avalyn Pharma Contineum Therapeutics ReAlta Life Sciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.